Pharmaceutical Technology

MAY 5, 2023

Under the collaborative research and development agreement (CRADA), respirable dry powder formulations of HMW-HA will be developed for prevention and treatment. This follows earlier research which demonstrated that HMW-HA yielded dry powder formulations with desirable aerosol performance when formulated with thin film freezing technology.

Development 162

Development In-Vivo In-Vitro Engineer 162

Drug Discovery World

APRIL 8, 2024

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Drug Discovery World

JANUARY 3, 2023

Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets. . The post Research partners hope to develop novel antibody-drug conjugates appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Development Research Drugs 52

Drug Discovery World

OCTOBER 4, 2023

This on-demand webinar shows how cloud implementation fosters accessibility and collaboration, revolutionising research across locations and companies. Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery.

Drugs 52

Drugs In-Vivo In-Vitro Research 52

Drug Discovery World

OCTOBER 4, 2023

This on-demand webinar from Revivify Signals shows how cloud implementation fosters accessibility and collaboration, revolutionising research across locations and companies.

In-Vivo 52

In-Vivo In-Vitro Drugs Research 52

Drug Discovery World

MAY 1, 2023

Download Emulate’s Introduction to Organ-on-a-Chip Technology eBook to learn about: What Organ-Chips are, how they work, and why they are transforming the way drugs are discovered and developed How Organ-Chips overcome the main challenges of conventional in vivo and in vitro models The wide variety of insights and endpoint analyses Organ-on-a-Chip (..)

In-Vivo 52

In-Vivo In-Vitro Gene Therapy Gene 52

Drug Discovery World

OCTOBER 27, 2023

Organ-chips combine cell culture with microfluidics to emulate the biological forces of different organ tissues and/or disease states, allowing pharmaceutical researchers to determine a drug candidates’ efficacy and toxicity ahead of clinical trials. Could organ-chips replace other research methods? Not yet, according to Ewart.

Research 72

Research Gene Therapy In-Vivo In-Vitro 72

Drug Discovery World

MAY 1, 2023

Download Emulate’s Introduction to Organ-on-a-Chip Technology eBook to learn about: What Organ-Chips are, how they work, and why they are transforming the way drugs are discovered and developed How Organ-Chips overcome the main challenges of conventional in vivo and in vitro models The wide variety of insights and endpoint analyses Organ-on-a-Chip (..)

In-Vivo 52

In-Vivo In-Vitro Gene Therapy Gene 52

Drug Discovery World

JUNE 26, 2023

The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany. These IgG4 antibodies have the potential to form the basis of a therapeutic drug candidate exhibiting strong potency and efficacy in vitro, ex vivo, and in vivo.

Allergies 52

Allergies Antibody In-Vivo In-Vitro 52

Drug Discovery World

APRIL 24, 2024

Under the terms of the risk-sharing partnership, Evotec will receive undisclosed research funding and may receive pre-clinical and clinical milestones and/or royalties dependent on the success of the programme. Dr Matthias Evers, Chief Business Officer of Evotec, said: “We are excited to enter this collaboration with Variant Bio.

Development 52

Development In-Vivo In-Vitro Genome 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Innovation S-curve for artificial Intelligence in the pharmaceutical industry In-silico drug discovery is a key innovation area in artificial Intelligence Drug research starts with the discovery stage that involves in vivo and in vitro models to shortlist lead drug compounds.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

Drug Discovery World

AUGUST 3, 2023

Sygnature Discovery has announced the acquisition of Canada-based contract research organisation NuChem Sciences. Founded in 2011, the company delivers discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology.

In-Vivo 52

In-Vivo In-Vitro Protein Marketing 52

Drug Discovery World

JUNE 27, 2023

Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area. We look forward to continuing our productive collaboration with our colleagues at IRBM in this compelling area of research.”

In-Vivo 52

In-Vivo In-Vitro Engineer Protein 52

BioTech 365

MARCH 9, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Scientists discover dynamic trimolecular G-quadruplex.As

Scientist 40

Scientist In-Vivo In-Vitro DNA 40

Drug Discovery World

APRIL 21, 2023

Purple Biotech shared the new results at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Florida, US. The study was led by researchers at The University of Texas MD Anderson Cancer Center. The study was led by researchers at The University of Texas MD Anderson Cancer Center.

Drugs 98

Drugs In-Vivo In-Vitro Protein 98

Drug Discovery World

MARCH 26, 2024

We were there to present the latest findings from our research. We were excited to unveil data showing that two distinct chemical series exhibit METTL1 inhibition in vitro at low nanomolar concentrations with minimal interference with other RNA and protein methyltransferases. MT: What’s next for STORM’s research?

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

APRIL 5, 2023

Italian research institute and contract research organisation IRBM has become the only company from outside the United States to join cancer drug discovery network the Chemical Biology Consortium (CBC). The post Only non-US company joins cancer drug discovery consortium appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

Drug Discovery World

MAY 9, 2023

Jantzen Sperry , PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. Mice have long been heroes of preclinical cancer research. Cancer is far more complex than the sum of its parts.

Development 52

Development Drugs In-Vivo Clinical Trials 52

Drug Discovery World

JUNE 6, 2023

In preclinical studies conducted by the company, BEN-34712 was neuroprotective in a patient-derived, disease-relevant in vitro motor neuron/iAstrocyte co-culture model, demonstrating significant efficacy in both sporadic and familial subtypes of ALS.

Drugs 52

Drugs In-Vivo In-Vitro Clinical Development 52

Drug Discovery World

JUNE 19, 2023

Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. This investment from the AFB FII fund stems from the AdBio-Inserm Transfert partnership announced in May 2022 to finance, support and grow Europe’s most innovative life science startups.

Development 52

Development Life Science In-Vivo In-Vitro 52

Drug Discovery World

JULY 3, 2023

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

Drug Discovery World

MARCH 8, 2023

Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2. Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumours.

Trials 52

Trials In-Vivo In-Vitro Antibody 52

Drug Discovery World

JANUARY 23, 2023

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Drug Discovery World

SEPTEMBER 26, 2022

UMC Utrecht and its partners have received a research grant to unravel how the intestinal microbiota can be exploited to boost cancer immunotherapy and limit therapy side-effects. . Close to €800,000 was awarded by Health~Holland to a public-private partnership between UMC Utrecht, Artizan Biosciences, Inc.

Bacteria 52

Bacteria Biobanking In-Vivo In-Vitro 52

The Pharma Data

MAY 3, 2021

In 2019, the division conducted a clinical trial to quantify the systemic absorption of sunscreen ingredients and has since published additional research on the topic. . Overall, the division’s cardiac safety research program yielded 25 publications and three FDA-sponsored clinical trials to assess cardiac safety biomarkers.

In-Vitro 52

In-Vitro Clinical Trials Clinical Trials In-Vivo 52

pharmaphorum

FEBRUARY 13, 2022

Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

Drug Discovery World

JUNE 30, 2023

Research tools, safety testing and regenerative medicines – these endless stem cell applications are powering precision, speed, and new modalities in drug development. Stem cells for use in drug discovery Stem cells are fast becoming an invaluable tool in the drug discovery process. This article is sponsored by Charles River.

Development 52

Development Drugs In-Vitro Gene Therapy 52

pharmaphorum

FEBRUARY 19, 2021

Khalili said: “This transformative financing will accelerate and support the research we have developed over the past decade. Khalili said: “This transformative financing will accelerate and support the research we have developed over the past decade. “We The post Could CRISPR cure HIV?

Gene Editing 105

Gene Editing In-Vivo DNA In-Vitro 105

Drug Discovery World

OCTOBER 20, 2022

This technology has resulted in the launch of a proprietary pipeline of several drug discovery projects, which now range from in vitro to in vivo phases, especially in oncology and immuno-oncology. .

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

The Pharma Data

JUNE 17, 2022

Researchers from the Institut Pasteur, Université Paris Cité, and INSERM examined 102 SARS-CoV-2 spike monoclonal antibodies cloned from the B cells of 10 COVID-19 convalescents. The research has its roots in a task force launched by the Institut Pasteur in the early days of the COVID-19 pandemic.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

Drug Discovery World

NOVEMBER 16, 2022

DDW Editor Reece Armstrong learns about Molecular Devices’ Organoid Innovation Centre (OIC) and how the company is aiming to advance research into 3D biology and organoids. . 2D biology has been used by pharmaceutical researchers for decades. 2D vs 3D .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Drug Discovery World

AUGUST 22, 2023

In many cases, it is also challenging to apply traditional bioequivalence methods or to ensure clarity about the comparison model (in-vitro/in-vivo) needed to gain health authority approval. Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost. What are complex generics?

Production 52

Production Bioequivalency In-Vivo In-Vitro 52

The Pharma Data

DECEMBER 9, 2020

With the launch of Overland, we are creating a robust research and development engine in parallel with the significant growth and opportunity presented by Asia’s evolving biotech industry. A solution could be at hand with Overland Pharmaceuticals. Below is a roundup of some of this week’s interesting news.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

JANUARY 4, 2021

ViGeneron’s recognized expertise in retinal gene therapy together with Biogen’s leading research, drug development and commercialization experience is a powerful combination that we believe will allow us to deliver more novel gene therapies to patients in need.”. The companies will work together on the in vivo proof of concept (POC).

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

The Pharma Data

JANUARY 6, 2021

The research collaboration is aimed at identifying novel lead compounds and repurposing existing drugs for rheumatoid arthritis and nonalcoholic steatohepatitis, leveraging Standigm’s AI-powered drug discovery platforms : Standigm BEST , Standigm Insight , and Standigm ASK. About Standigm. Standigm is an AI-driven drug discovery company.

FDA Approval 52

FDA Approval Life Science Drugs In-Vivo 52

Drug Discovery World

JULY 22, 2022

As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. Although immunotherapy has revolutionised cancer therapy, the effectiveness of currently available immunotherapies varies significantly across patients and treatment types.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

The Pharma Data

MARCH 29, 2022

There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1, 6,7 This study also showed Evusheld reduced viral burden and limited inflammation in the lungs (in vivo) across all Omicron variants.6. Christoph D.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52